Literature DB >> 18649394

Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.

Gabor G Kovacs1, Ivan J Milenkovic, Matthias Preusser, Herbert Budka.   

Abstract

Aggregated alpha-synuclein is the hallmark of Parkinson's disease (PD), diffuse Lewy body disease (DLBD), and multiple system atrophy (MSA). Physiologically, alpha-synuclein ensures normal functions of dopamine transporter (DAT) and tyrosine hydoxylase. In alpha-synucleinopathies, it accumulates in neuronal cytoplasm and neurites through several stages. It is unclear whether the accumulation of pathological alpha-synuclein in the substantia nigra in PD correlates with the dopaminergic deficit in the striatal target. We evaluated the impact of the nigral burden of pathological alpha-synuclein immunoreactivity in 27 alpha-synucleinopathy brains by morphometric immunohistochemistry. DAT immunoreactivity in the striatum inversely correlates with the total alpha-synuclein burden in the substantia nigra but not with cytoplasmic inclusion counts only. This result has implications for imaging, clinicopathological correlative studies, and staging of the disease process. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18649394     DOI: 10.1002/mds.22207

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  21 in total

1.  Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer's disease.

Authors:  Tabea H Schauer; Maximilian Lochner; Gabor G Kovacs
Journal:  J Neural Transm (Vienna)       Date:  2012-06-05       Impact factor: 3.575

2.  A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease.

Authors:  Richard A Armstrong; Paul T Kotzbauer; Joel S Perlmutter; Meghan C Campbell; Kyle M Hurth; Robert E Schmidt; Nigel J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2013-08-31       Impact factor: 3.575

Review 3.  Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease.

Authors:  Saranya Sundaram; Rachel L Hughes; Eric Peterson; Eva M Müller-Oehring; Helen M Brontë-Stewart; Kathleen L Poston; Afik Faerman; Chloe Bhowmick; Tilman Schulte
Journal:  Neurosci Biobehav Rev       Date:  2019-05-24       Impact factor: 8.989

4.  Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.

Authors:  Junchao Tong; Lee-Cyn Ang; Belinda Williams; Yoshiaki Furukawa; Paul Fitzmaurice; Mark Guttman; Isabelle Boileau; Oleh Hornykiewicz; Stephen J Kish
Journal:  Neurobiol Dis       Date:  2015-06-21       Impact factor: 5.996

Review 5.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

6.  Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.

Authors:  Gaia Skibinski; Ken Nakamura; Mark R Cookson; Steven Finkbeiner
Journal:  J Neurosci       Date:  2014-01-08       Impact factor: 6.167

7.  The diagnostic value of minor salivary gland biopsy in clinically diagnosed patients with Parkinson's disease: comparison with DAT PET scans.

Authors:  Liyan Gao; Huimin Chen; Xin Li; Fangfei Li; Qiaohong Ou-Yang; Tao Feng
Journal:  Neurol Sci       Date:  2015-03-28       Impact factor: 3.307

Review 8.  Is Braak staging valid for all types of Parkinson's disease?

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2018-06-25       Impact factor: 3.575

Review 9.  Formation and development of Lewy pathology: a critical update.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

10.  Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration.

Authors:  Anjan P Pandey; Farzin Haque; Jean-Christophe Rochet; Jennifer S Hovis
Journal:  Biophys J       Date:  2009-01       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.